Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CR01

A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Lymphoma

Presenter:  Debra Tesoro, RPh, BCOP, Department of Medicine, Division of Medical Oncology, Siteman Cancer Center, St Louis, MO

Co-Authors: Richard Fong, PharmD, BCOP, Department of Pharmaceutical Sciences, University of California San Francisco, San Francisco, CA; Jeremy Deni, PharmD, BCPS, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Juan Pablo Alderuccio, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Brad Kahl, MD, Department of Medicine, Oncology Division, Washington University, St. Louis, MO; Weiyun Ai, MD, PhD, Department of Medicine, Hematology/Oncology, University of California San Francisco, San Francisco, CA; David Ungar, MD, ADC Therapeutics America, Murray Hill, NJ; Turk Kilavuz , MD, ADC Therapeutics America, Murray Hill, NJ; Eric Yu, PhD, ADC Therapeutics America, Murray Hill, NJ; Yajuan Qin, MD, PhD, ADC Therapeutics America, Murray Hill, NJ; Daniel Nobel, PharmD, BCOP, BCPS, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

BACKGROUND: Loncastuximab tesirine-lpyl is an antibody–drug conjugate that includes an anti-CD19 antibody that is conjugated to the alkylating agent SG3199, a pyrrolobenzodiazepine dimer cytotoxin designed to target and kill CD19-expressing malignant B-cells. Loncastuximab tesirine is indicated by the FDA for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after ≥2 previous systemic therapies.

OBJECTIVE: To describe the incidence, time to onset, and management of grade ≥3 myelosuppression of patients receiving loncastuximab tesirine for relapsed or refractory DLBCL in the LOTIS-1 and LOTIS-2 clinical trials.

METHOD: This pooled safety analysis included patients with relapsed or refractory DLBCL from the phase 1, dose-finding LOTIS-1 clinical trial1 and the pivotal, single-arm, phase 2 LOTIS-2 clinical trial2 (data cutoff, March 1, 2021). Loncastuximab tesirine was administered every 3 weeks. LOTIS-1 used doses ranging from 0.015 mg/kg to 0.2 mg/kg, and LOTIS-2 used the approved dose in the prescribing information (0.15 mg/kg for 2 cycles, followed by 0.075 mg/kg for subsequent cycles). Growth factors were permitted, according to ASCO guidelines. Laboratory values were monitored at least weekly for the first 2 cycles and every 3 weeks thereafter. Myelosuppression events were graded according to the Common Terminology Criteria for Adverse Events version 4.0.

RESULTS: In the pooled population of patients who received an initial dose of 0.15 mg/kg (N = 215), grade ≥3 neutropenia, thrombocytopenia, and anemia occurred in 69 (32.1%), 43 (20%), and 27 (12.6%) patients, respectively. Febrile neutropenia occurred in 7 (3.3%) patients. In most patients with grade 3/4 neutropenia, the onset occurred in the first 4 months, and in most patients with grade 3/4 thrombocytopenia or anemia, the onset occurred in the first 2 months. Dose delays were the result of grade ≥3 neutropenia, thrombocytopenia, anemia, or febrile neutropenia in 22 (10.2%), 18 (8.4%), 3 (1.4%), and 1 (0.5%) patients, respectively. Treatment discontinuation occurred because of grade ≥3 thrombocytopenia and neutropenia in 5 (2.3%) and 1 (0.5%) patients, respectively. No treatment discontinuation was associated with anemia or febrile neutropenia. Neutrophil growth factors were administered as prophylaxis to 33 (15.3%) patients and as treatment to 56 (26.0%) patients.

CONCLUSION: The incidences of grade ≥3 neutropenia, thrombocytopenia, and anemia were <35%, and the incidence of febrile neutropenia was low. Although grade 3/4 neutropenia and thrombocytopenia were among the leading causes of dose delays, the majority of myelosuppression cases were manageable with dose delays and did not require dose reductions or treatment discontinuation.

  1. ClinicalTrials.gov. Identifier: NCT02669017. Study of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL). https://clinicaltrials.gov/ct2/show/NCT02669017?term=NCT02669017&draw=2&rank=1.
  2. ClinicalTrials.gov. Identifier: NCT03589469. Study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2). https://clinicaltrials.gov/ct2/show/NCT03589469?term=NCT03589469&draw=2&rank=1.
Related Items
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, CAR T-Cell Therapy, Lymphoma
Hepatitis B Virus Infection Monitoring in Patients with Lymphoma Receiving Anti-CD20 Monoclonal Antibodies
Christopher Sinoimeri, PharmD, Bryan Do, PharmD, BCOP, Sheree Chen, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Original Article, Lymphoma, Immunotherapy, Infections
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Lymphoma, CAR T-Cell Therapy
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.